Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Nxera Pharma to Receive $3 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Nxera Pharma Proposes Changes to its Board of Directors
Consolidated Financial Results for the FY2025 (IFRS)
Nxera Pharma to Record Extraordinary Loss on Impairment of Shares of Consolidated Subsidiary (Non-Consolidated)
Notice Concerning Reduction of Executive Compensation
Variance of Consolidated Results Between the Year Ended 31 December 2025 and the Previous Year
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Nxera Announces Conclusion of Buyback for Existing Convertible Bonds
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
Nxera Announces Results of Buyback and Consent Solicitation for Existing Convertible Bonds
Notice Regarding Receipt of Dividends from Consolidated Subsidiary
Notice Regarding Change in Major Shareholder and Largest Shareholder
[Summary] Nxera Announces Buyback and Consent Solicitation for Existing Convertible Bonds
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan